D'Arminio Monforte A - Search Results

1

A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study.

Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, D'Arminio Monforte A, Hermans P, Goebel FD, Blaxhult A, Kirk O, Phillips AN; EuroSIDA Study Group. Lundgren JD, et al. J Infect Dis. 2002 Jan 15;185(2):178-87. doi: 10.1086/338267. Epub 2002 Jan 3. J Infect Dis. 2002. PMID: 11807691 Free article.

2

Tuberculosis among European patients with the acquired immune deficiency syndrome. The AIDS in Europe Study Group.

Sudre P, Hirschel BJ, Gatell JM, Schwander S, Vella S, Katlama C, Ledergerber B, d'Arminio Monforte A, Goebel FD, Pehrson PO, Pedersen C, Lundgren JD. Sudre P, et al. Tuber Lung Dis. 1996 Aug;77(4):322-8. doi: 10.1016/s0962-8479(96)90096-9. Tuber Lung Dis. 1996. PMID: 8796247

3

Italian multicentre study of didanosine compassionate use in advanced HIV infection. Italian BMS-906 Study Group.

d'Arminio Monforte A, Musicco M, Galli M, Paga C, La Regina A, Lazzarin A, Angarano G, Milazzo F, Gritti F, Arlotti M, Mazzotta F, Visco G, Aiuti F, Moroni M. d'Arminio Monforte A, et al. Eur J Clin Microbiol Infect Dis. 1997 Feb;16(2):135-42. doi: 10.1007/BF01709472. Eur J Clin Microbiol Infect Dis. 1997. PMID: 9105840 Clinical Trial.

4

Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection.

d'Arminio Monforte A, Testa L, Adorni F, Chiesa E, Bini T, Moscatelli GC, Abeli C, Rusconi S, Sollima S, Balotta C, Musicco M, Galli M, Moroni M. d'Arminio Monforte A, et al. AIDS. 1998 Sep 10;12(13):1631-7. doi: 10.1097/00002030-199813000-00010. AIDS. 1998. PMID: 9764782 Clinical Trial.

5

Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.

Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD. Mocroft A, et al. Lancet. 1998 Nov 28;352(9142):1725-30. doi: 10.1016/s0140-6736(98)03201-2. Lancet. 1998. PMID: 9848347

6

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.

Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzáles-Lahoz J, d'Arminio Monforte A, Proenca R, Phillips AN, Lundgren JD, Reiss P. Weverling GJ, et al. Lancet. 1999 Apr 17;353(9161):1293-8. doi: 10.1016/s0140-6736(99)03287-0. Lancet. 1999. PMID: 10218526

7

Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group.

Mocroft A, Kirk O, Barton SE, Dietrich M, Proenca R, Colebunders R, Pradier C, dArminio Monforte A, Ledergerber B, Lundgren JD. Mocroft A, et al. AIDS. 1999 May 28;13(8):943-50. doi: 10.1097/00002030-199905280-00010. AIDS. 1999. PMID: 10371175

8

Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.

d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, Angarano G, Colangeli V, De Luca A, Ippolito G, Caggese L, Soscia F, Filice G, Gritti F, Narciso P, Tirelli U, Moroni M. d'Arminio Monforte A, et al. AIDS. 2000 Mar 31;14(5):499-507. doi: 10.1097/00002030-200003310-00005. AIDS. 2000. PMID: 10780712 Clinical Trial.

9

Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.

Mussini C, Pezzotti P, Govoni A, Borghi V, Antinori A, d'Arminio Monforte A, De Luca A, Mongiardo N, Cerri MC, Chiodo F, Concia E, Bonazzi L, Moroni M, Ortona L, Esposito R, Cossarizza A, De Rienzo B. Mussini C, et al. J Infect Dis. 2000 May;181(5):1635-42. doi: 10.1086/315471. Epub 2000 May 15. J Infect Dis. 2000. PMID: 10823763 Clinical Trial.

10

Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy.

Bini T, Testa L, Chiesa E, Adorni F, Abeli C, Castelnuovo B, Melzi S, Sollima S, Bongiovanni M, d'Arminio Monforte A. Bini T, et al. J Acquir Immune Defic Syndr. 2000 Jun 1;24(2):115-22. doi: 10.1097/00126334-200006010-00005. J Acquir Immune Defic Syndr. 2000. PMID: 10935686 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

598 results

Search Page

Filters